查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1859019

液体切片市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

Liquid Biopsy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球液体活检市场价值为 48 亿美元，预计到 2034 年将以 15.8% 的复合年增长率增长至 207 亿美元。

液体活检市场 - IMG1

癌症诊断技术的不断进步、非侵入性检测方法的普及、癌症发病率的上升以及人们对早期检测意识的增强，共同推动了液体活检的发展。随着全球医疗系统增加基础设施投入并扩大筛检覆盖范围，可扩展、精准的工具（例如液体活检）的需求持续成长。对早期识别和精准医疗的日益重视，为液体活检在临床应用中的推广提供了沃土。此检测方法可以直接从体液中检测和分析肿瘤来源的生物标记物，例如游离DNA、循环肿瘤细胞和细胞外囊泡，为传统的组织活检提供了更安全、更快捷的替代方案。液体活检的应用范围涵盖癌症诊断、突变追踪和治疗监测，正逐渐成为一种变革性的解决方案，尤其适用于高风险和弱势患者群体。它能够在最大限度降低手术风险的同时提供可操作的见解，因此在研究机构、医院和诊断实验室中得到了更广泛的应用。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 48亿美元
预测值 207亿美元
复合年增长率 15.8%

2024年，循环肿瘤细胞（CTC）市场规模预计将达19亿美元。这些细胞从原发肿瘤脱落并通过血液循环进入体内，对于即时揭示肿瘤动态变化具有重要价值。从成像平台到微流控技术，用于分离和分析CTC的技术正帮助临床医生了解肿瘤的演化、抗药性机制和基因谱。 CTC的非侵入性和在即时监测中的作用，使其成为液体活检生态系统中日益重要的组成部分，并拓展了其临床应用价值。

预计到2024年，癌症应用领域将占据85.8%的市场。全球癌症负担的持续加重，不断提升了对更快、更微创、更精准的诊断方法的需求。液体活检有望更早发现恶性肿瘤，更有效地制定个人化治疗方案，并在无需手术干预的情况下监测治疗反应。其在肿瘤学领域的日益普及，源自于对更个人化、以患者为中心的治疗策略的需求，这些策略能够缩短诊断时间并改善治疗效果。

2024年北美液体切片市场规模达20亿美元，预计2034年将达84亿美元。该地区的领先地位源于其强大的生物技术研究生态系统、政府在肿瘤领域的大量投资以及对先进诊断方案日益增长的需求。临床和研究领域的高普及率，以及持续的产品创新和审批，都巩固了该地区的市场地位。患者和医疗服务提供者对液体活检的认知度不断提高，以及公共和私人资金支持的强劲研发管线，也为该地区的成长注入了新的动力。

推动全球液体切片市场发展的关键企业包括Myriad Genetics、BIOCEPT、Thermo Fisher Scientific、Guardant Health、F. Hoffmann La Roche、Menarini Silicon Biosystems、Lucene Health、Oncimmune、Illumina、EPIGENOMICS、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、Healthx、Healthn、BioxAn、THealthEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labories、Healthx、BioxAngle、Freenome Holdings、QIAGEN、Bio-Rad Labor）。这些企业正采取多角化策略来巩固和提升其市场地位。其主要重点在于拓展早期癌症检测和监测解决方案的研发管线。与科研机构和医院的策略合作有助于加速临床验证，并扩大新兴技术的应用范围。许多公司正在开发由人工智慧驱动的平台，以提高生物标记检测的准确性并简化结果解读。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

  • 产业生态系分析
  • 产业影响因素
    • 成长驱动因素
      • 癌症诊断技术的不断进步
      • 人们越来越倾向于非侵入性疾病诊断
      • 全球癌症发生率不断上升
      • 人们越来越关注疾病的早期诊断
    • 产业陷阱与挑战
      • 严格的监管框架
      • 缺乏熟练的专业人员
    • 市场机会
      • 扩大多癌种早期检测（MCED）测试
  • 成长潜力分析
  • 监管环境
  • 技术进步
    • 当前技术趋势
    • 新兴技术
  • 供应链分析
  • 报销方案
  • 2024年定价分析
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL 分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估算与预测：依生物标记划分，2021-2034年

  • 主要趋势
  • 循环肿瘤细胞（CTC）
  • 循环肿瘤DNA
  • 无细胞DNA
  • 细胞外囊泡
  • 其他生物标誌物

第六章：市场估算与预测：依产品划分，2021-2034年

  • 主要趋势
  • 消耗品
    • 试剂盒和试剂
    • 检测和检测组
  • 仪器
  • 服务

第七章：市场估计与预测：依疾病适应症划分，2021-2034年

  • 主要趋势
  • 癌症
    • 肺癌
    • 乳癌
    • 大肠直肠癌
    • 摄护腺癌
    • 其他癌症
  • 非癌症
    • 非侵入性产前检测
    • 器官移植
    • 传染病检测

第八章：市场估算与预测：依临床应用用途划分，2021-2034年

  • 主要趋势
  • 治疗监测
  • 预后和復发监测
  • 治疗选择
  • 诊断和筛检

第九章：市场估计与预测：依技术划分，2021-2034年

  • 主要趋势
  • 多基因平行分析（NGS）
  • 单基因分析（PCR微阵列）

第十章：市场估计与预测：依最终用途划分，2021-2034年

  • 主要趋势
  • 医院
  • 研究实验室
  • 临床实验室
  • 其他最终用途

第十一章：市场估计与预测：按地区划分，2021-2034年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋

第十二章：公司简介

  • Angle
  • BIOCEPT
  • Bio-Rad Laboratories
  • EPIGENOMICS
  • F. Hoffmann La Roche
  • Freenome Holdings
  • Guardant Health
  • Illumina
  • Lucene Health
  • MDxHealth
  • Menarini Silicon Biosystems
  • Myriad Genetics
  • Oncimmune
  • QIAGEN
  • Thermo Fisher Scientific
简介目录
Product Code: 3775

The Global Liquid Biopsy Market was valued at USD 4.8 billion in 2024 and is estimated to grow at a CAGR of 15.8% to reach USD 20.7 billion by 2034.

Liquid Biopsy Market - IMG1

The growth is being fueled by rising advancements in cancer diagnostics, a shift toward non-invasive methods, increasing cancer prevalence, and greater awareness around early detection. As healthcare systems globally invest in infrastructure and expand screening access, demand for scalable, accurate tools like liquid biopsy continues to accelerate. The growing focus on early-stage identification and precision medicine is creating fertile ground for the integration of liquid biopsy into clinical settings. The test allows the detection and analysis of tumor-derived biomarkers such as cell-free DNA, circulating tumor cells, and extracellular vesicles directly from bodily fluids, offering a safer and faster alternative to traditional tissue biopsies. With applications spanning cancer diagnosis, mutation tracking, and treatment monitoring, liquid biopsy is proving to be a transformative solution, especially for high-risk and vulnerable patient populations. Its ability to minimize procedural risks while delivering actionable insights supports broader adoption across research institutions, hospitals, and diagnostic labs.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$4.8 Billion
Forecast Value$20.7 Billion
CAGR15.8%

In 2024, the circulating tumor cells segment generated USD 1.9 billion. These cells, which detach from primary tumors and travel through the bloodstream, are valuable in revealing tumor dynamics in real time. Technologies used to isolate and analyze CTCs, ranging from imaging platforms to microfluidics, are enabling clinicians to understand tumor evolution, resistance mechanisms, and genetic profiles. Their non-invasive nature and role in real-time monitoring make CTCs an increasingly important component of the liquid biopsy ecosystem, broadening its clinical relevance.

The cancer application segment held an 85.8% share in 2024. The steadily rising global burden of cancer continues to elevate the demand for faster, less invasive, and highly precise diagnostic methods. Liquid biopsy offers the potential to detect malignancies earlier, tailor therapies more effectively, and monitor responses without requiring surgical interventions. Its growing adoption in oncology is being driven by the need for more personalized, patient-centric treatment strategies that reduce time-to-diagnosis and improve care outcomes.

North America Liquid Biopsy Market generated USD 2 billion in 2024 and is expected to reach USD 8.4 billion by 2034. The region's leadership stems from its strong biotechnology research ecosystem, significant government investments in oncology, and rising demand for advanced diagnostic options. High adoption rates across clinical and research environments, along with regular product innovation and approvals, are helping solidify the region's position. Rising awareness among patients and providers, along with robust R&D pipelines supported by public and private funding, is adding momentum to regional growth.

Key players shaping the Global Liquid Biopsy Market include Myriad Genetics, BIOCEPT, Thermo Fisher Scientific, Guardant Health, F. Hoffmann La Roche, Menarini Silicon Biosystems, Lucene Health, Oncimmune, Illumina, EPIGENOMICS, Freenome Holdings, QIAGEN, Bio-Rad Laboratories, MDxHealth, and Angle. Companies in the Liquid Biopsy Market are deploying multi-faceted strategies to build and protect their market positions. A primary focus lies in expanding R&D pipelines for early-stage cancer detection and monitoring solutions. Strategic collaborations with research institutes and hospitals help accelerate clinical validation and widen access to emerging technologies. Many firms are developing AI-driven platforms to improve the accuracy of biomarker detection and streamline interpretation.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Biomarkers trends
    • 2.2.3 Product trends
    • 2.2.4 Disease indication trends
    • 2.2.5 Clinical application trends
    • 2.2.6 Technology trends
    • 2.2.7 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Continuous technological advancements in cancer diagnostics
      • 3.2.1.2 Increasing preference for non-invasive disease diagnosis
      • 3.2.1.3 Growing prevalence of cancer worldwide
      • 3.2.1.4 Rising awareness regarding early disease diagnosis
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory framework
      • 3.2.2.2 Lack of skilled professionals
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of multi-cancer early detection (MCED) tests
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technological advancements
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Supply chain analysis
  • 3.7 Reimbursement scenario
  • 3.8 Pricing analysis, 2024
  • 3.9 Future market trends
  • 3.10 Gap analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Biomarkers, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Circulating tumor cells (CTC)
  • 5.3 Circulating tumor DNA
  • 5.4 Cell-free DNA
  • 5.5 Extracellular vesicles
  • 5.6 Other biomarkers

Chapter 6 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Consumables
    • 6.2.1 Kits and reagents
    • 6.2.2 Assay and panels
  • 6.3 Instruments
  • 6.4 Services

Chapter 7 Market Estimates and Forecast, By Disease Indication, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Cancer
    • 7.2.1 Lung cancer
    • 7.2.2 Breast cancer
    • 7.2.3 Colorectal cancer
    • 7.2.4 Prostate cancer
    • 7.2.5 Other cancers
  • 7.3 Non-cancer
    • 7.3.1 Non-invasive prenatal testing
    • 7.3.2 Organ transplantation
    • 7.3.3 Infectious disease testing

Chapter 8 Market Estimates and Forecast, By Clinical Application Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Treatment monitoring
  • 8.3 Prognosis and recurrence monitoring
  • 8.4 Treatment selection
  • 8.5 Diagnosis and screening

Chapter 9 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 Multi-gene parallel analysis (NGS)
  • 9.3 Single gene analysis (PCR Microarrays)

Chapter 10 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 Hospitals
  • 10.3 Research Laboratories
  • 10.4 Clinical Laboratories
  • 10.5 Other end use

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 11.1 Key trends
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Netherlands
  • 11.4 Asia Pacific
    • 11.4.1 China
    • 11.4.2 India
    • 11.4.3 Japan
    • 11.4.4 Australia
    • 11.4.5 South Korea
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Argentina
  • 11.6 Middle East and Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 South Africa
    • 11.6.3 UAE

Chapter 12 Company Profiles

  • 12.1 Angle
  • 12.2 BIOCEPT
  • 12.3 Bio-Rad Laboratories
  • 12.4 EPIGENOMICS
  • 12.5 F. Hoffmann La Roche
  • 12.6 Freenome Holdings
  • 12.7 Guardant Health
  • 12.8 Illumina
  • 12.9 Lucene Health
  • 12.10 MDxHealth
  • 12.11 Menarini Silicon Biosystems
  • 12.12 Myriad Genetics
  • 12.13 Oncimmune
  • 12.14 QIAGEN
  • 12.15 Thermo Fisher Scientific